Comparative Pharmacology
Head-to-head clinical analysis: AMIPAQUE versus OMNIPAQUE 140.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIPAQUE versus OMNIPAQUE 140.
AMIPAQUE vs OMNIPAQUE 140
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metrizamide, a non-ionic iodinated contrast agent, attenuates X-rays due to iodine content, enhancing radiographic imaging. It distributes in extracellular fluid and does not cross intact blood-brain barrier; in subarachnoid space, it outlines neural structures.
Radiopaque contrast agent that attenuates X-rays due to iodine content, enhancing vascular and tissue visualization.
200-300 mg iodine/kg body weight intravenously, maximum 60 g iodine per administration.
Intravascular: 50-200 mL (containing 7.0-28.0 g iodine) per procedure, administered intravenously as a bolus or infusion; dose depends on imaging modality and body region. Intrathecal: 6-15 mL (containing 0.84-2.1 g iodine) administered via lumbar puncture for myelography.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment (up to 20-30 hours in severe renal failure).
Terminal elimination half-life: 1–2 hours; prolonged in renal impairment (up to 30–40 hours in severe dysfunction).
Primarily renal excretion via glomerular filtration; approximately 90-95% of the dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary route.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent